49th week of 2010 patent applcation highlights part 38 |
Patent application number | Title | Published |
20100310599 | Orally Bioavailable Lipid-Based Constructs - The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof. | 2010-12-09 |
20100310600 | SELECTIVE AGONIST OF TOLL-LIKE RECEPTOR 3 - A mismatched double-stranded ribonucleic acid, which is an agonist for Toll-like receptor 3 (TLR3), is used in vitro or in vivo as an antimicrobial agent, antiproliferative agent, and/or immunostimulant. Poly(l:C | 2010-12-09 |
20100310601 | Adeno-Associated Virus Materials and Methods - The present invention provides adeno-associated virus (AAV) materials and methods which are useful for DNA delivery to cells. More particularly, the invention provides recombinant AAV (rAAV) genomes, methods for packaging rAAV genomes, stable host cell lines producing rAAV and methods for delivering genes of interest to cells utilizing the rAAV. Particularly disclosed are rAAV useful in generating immunity to human immunodeficiency virus-1 and in therapeutic gene delivery for treatment of neurological disorders. | 2010-12-09 |
20100310602 | SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS - Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: | 2010-12-09 |
20100310603 | TEM8 as an Adjuvant and Uses Thereof - The present invention discloses a composition comprising an immunogenic sequence or a fragment thereof and TEM8 or a fragment thereof, where the TEM8 or the fragment functions as an adjuvant and enhances the eilicitation of immune responses mediated by the immunogenic sequence or the fragment thereof. Also disclosed herein is the use of such compositions in the treatment of cancer or pathogen associated diseases. | 2010-12-09 |
20100310604 | RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN TRANSGENIC PLANTS EXPRESSING HEMAGGLUTININ - A method for synthesizing influenza virus-like particles (VLPs) within a plant or a portion of a plant is provided. The method involves expression of influenza HA in plants and the purification by size exclusion chromatography. The invention is also directed towards a VLP comprising influenza HA protein and plants lipids. The invention is also directed to a nucleic acid encoding influenza HA as well as vectors. The VLPs may be used to formulate influenza vaccines, or may be used to enrich existing vaccines. | 2010-12-09 |
20100310605 | ANTI-HCV VACCINE AND PREPARATION METHODS AND USES THEREOF - An anti-HCV vaccine, which is prepared through recombination of an NS gene in series, including NS3/NS4 and NS4/NS5, with an adenovirus vector. The preparation methods and uses of the anti-HCV vaccine. | 2010-12-09 |
20100310606 | VACCINATION WITH KILLED BUT METABOLICALLY ACTIVE (KBMA) PROTOZOANS WITH TOLL-LIKE RECEPTOR AGONISTS - This invention provides compositions for inducing an immune response in a vertebrate host against a protozoan parasite. In certain embodiments the composition comprises a protozoan parasite comprising a psoralen-modified DNA, whereby said protozoan parasite is killed but metabolically active (KBMA); and optionally a Toll-like receptor agonist. | 2010-12-09 |
20100310607 | PHARMACEUTICAL FORMULATIONS - The present invention relates to oral formulations comprising an active agent comprising at least one of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid, salts of 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid or buffered 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-propanoic acid. | 2010-12-09 |
20100310608 | SEQUESTERING SUBUNIT AND RELATED COMPOSITIONS AND METHODS - A sequestering subunit comprising an aversive agent and a blocking agent, wherein the blocking agent substantially prevents release of the aversive agent from the sequestering subunit in the gastrointestinal tract for a time period that is greater than 24 hours; a composition comprising a sequestering subunit in releasable form, wherein, optionally, the mechanical fragility of the sequestering subunit is the same as the mechanical fragility of the therapeutic agent in releasable form; a capsule or tablet comprising a sequestering subunit and a therapeutic agent; and a method of preventing abuse of a therapeutic agent. | 2010-12-09 |
20100310609 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient for treating an inflammatory neurodegenerative condition or disease (e.g., multiple sclerosis (MS), Parkinson's disease (PD), Alzheimer's disease (AD)) or at least one symptom thereof. The electrokinetically-altered fluids or therapeutic compositions and methods include electrokinetically-altered ionic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential and/or conductance, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 2010-12-09 |
20100310610 | COMPOSITIONS AND METHODS FOR CONTROLLING DRUG LOSS AND DELIVERY IN TRANSDERMAL DRUG DELIVERY SYSTEMS - A transdermal delivery system is provided for the topical application of one or more active agents contained in one or more polymeric and/or adhesive carrier layers, proximate to a non-drug containing polymeric and/or adhesive coating that is applied to either the transdermal system's backing or release liner. The transdermal delivery device is manufactured to optimize drug loading while providing desirable adhesion to skin or mucosa as well as providing modulation of the drug delivery and profile. | 2010-12-09 |
20100310611 | Parenteral and oral formulations of benzimidazoles - Provided herein are drug delivery systems, such as self-nanoemulsifying drug delivery systems, self-emulsifying drug delivery systems and parenteral microemulsion formulations, suitable for parenteral or oral delivery to a subject. The drug delivery systems may comprise a benzimidazole derivative, e.g., mebendazole, an oil, a surfactant, a cosurfactant and a dipolar aprotic solvent in a microemulsion formulation. Also provided are methods for improving the bioavailability of a benzimidazole derivative during treatment of a pathophysiological condition by using a formulation combining a particular emulsion droplet diameter and ratio of the surfactant:cosurfactant therein, for increasing concentration and retention of a benzimidazole derivative in the lung via a parenterally administerable microemulsion with droplet size of about 35 nm to less than 100 nm and for defining hemolytically safe microemulsions of a benzimidazole derivative during a therapeutic treatment via a parenterally administerable microemulsion with a surfactant:cosurfactant content by weight of about 6% to 48%. | 2010-12-09 |
20100310612 | Medicament for the Treatment of Cancer of the Pancreas - The invention relates to a suspension of red corpuscles encapsulating asparaginase as a medicament for treating pancreatic cancer. It in particular concerns a therapeutic composition or medicament intended for the treatment of pancreatic cancer, containing an effective quantity of such a suspension of red corpuscles. | 2010-12-09 |
20100310613 | DRUG DELIVERY SYSTEM - A drug delivery system for the controlled release of a pharmaceutically-active compound by oral route comprises an intercalate of a layered double hydroxide having, before intercalation, layers of metal hydroxides, and having intercalated therein a pharmaceutically-active compound having at least one anionic group. A preferred layered double hydroxide is one that has layers which comprise [LiAl | 2010-12-09 |
20100310614 | Stannous Chloride Compositions - The invention relates to a particulate composition comprising:
| 2010-12-09 |
20100310615 | COMPOSITIONS COMPRISING STILBENE POLYPHENOL DERIVATIVES AND USE THEREOF FOR COMBATING THE AGEING OF LIVING ORGANISMS AND DISEASES AFFECTING SAME - The invention relates to compositions comprising pholyphenol derivatives, characterised in that said polyphenols contain monomers, oligomers or polymers with units having formula (I), said units being characterised by the simultaneous presence of a resorcinol nucleus (nucleus A) and a para-phenol nucleus (nucleus B) which are interconnected by a carbon bond C, said derivatives being over-activated, in respect of the nucleophilic power thereof, by alkylation of at least one phenol function of each constituent monomer unit and stabilised by sterification by mixtures of fatty acids in proportions reflecting those of vegetable oils formed mainly by unsaturated fatty acids of all of the other phenol functions. The invention is suitable for use in cosmetics, dietetics and therapeutics. | 2010-12-09 |
20100310616 | METHOD OF COSMETIC CARE STIMULATING MITOCHONDRIAL ACONITASE - The invention relates to a cosmetic care method for preventing or retarding the appearance of the signs of ageing of the skin or for attenuating the effects thereof. | 2010-12-09 |
20100310617 | WATER-IN-OIL EMULSION SYSTEM AND PREPARATION PROCESS THEREOF - The present invention relates to a water-in-oil system, which comprises 1.5-9 wt. % of hydrophobic silica, 0.1-5 wt. % of a water-in-oil emulsifier, 10-40 wt. % of an oil phase, with the content of the oil phase not including the hydrophobic silica and water-in-oil emulsifier therein, and 55-85 wt % of a water phase; with the proviso that said hydrophobic silica is not AEROSIL® RY200 hydrophobic fumed silica, and it is excluded the formulation comprising the components of: polyoxyalkylene modified polysiloxane SH3775E, a compound of the following formula (I) and hydrophobic fumed silica AEROSIL® R812, in which the weight ratio of SH3775E to the compound of formula (I) is 05, and the weight ratio of the sum of SH3775E and the compound of formula (I) to hydrophobic fumed silica AEROSIL® R812 is also 05. | 2010-12-09 |
20100310618 | COSMETIC HAIR COMPOSITION - The hair cosmetic composition contains a solvent-containing silicone emulsion (A) which is prepared by emulsifying a mixture of high-molecular-weight polyorganosiloxane (a) obtained by emulsion polymerization and a volatile solvent (b), a surfactant (B) and water (C). The component solvent-containing silicone emulsion (A) is contained at a ratio of 0.1-10 wt % as a total amount of the high-molecular-weight polyorganosiloxane (a) and the volatile solvent (b). And, the component surfactant (B) is contained at a ratio of 0.05-40 wt %. Hair is provided with outstanding smoothness and softness, and particularly good finger combing when rinsing the hair. | 2010-12-09 |
20100310619 | Sonny's Miracle - An ointment made of sunflower oil and yellow candle (paraffin); the candles are dissolved in the heated sunflower oil container; the yellow candle and sunflower oil mixture turns into a cream which then the ointment is formed, while hot the ointment is pasted on a clean cloth by dipping the cloth into the heated cream mixture; the pasted cloth is kept chilled in the freezer until is ready to be applied; the ointment is applied chilled by applying the pasted cloth into the bum wound and is left on for 10 hours or less, after 10 hours the pasted cloth is replaced with another pasted cloth and the procedure is repeated until the ointment heals the wound, the chilled ointment immediately cools the bum wound and keeps it cool, removes the pain, heals the wound, does not leave wrinkles in the skin | 2010-12-09 |
20100310620 | INSECT ATTRACTANTS AND THEIR USE IN METHODS OF INSECT CONTROL - The present invention utilizes a fatty acid as an attractant in a method of attracting whiteflies. By using a fatty acid as a whitefly attractant, it is possible to attract whiteflies to a desired location. The fatty acid can be used in a lure or other propagator to provide a dispersion of fatty acid in the air, the variation in the concentration of the fatty acid in the air being such that a whitefly is attracted to the lure as the source of the fatty acid. The use of a fatty acid as an attractant results in significantly higher levels of attraction, as measured by the number of whiteflies attracted to a sticky trap, as compared to the use of colour alone. | 2010-12-09 |
20100310621 | Controlled Iodine Release Particle Micro-Biocide - A controlled release molecular iodine biocide for use in human cavities especially the vaginal, penile canal, nasal passages and rectum. Particles can be functionalized with epithelial cell binding molecules and lymphocyte-binding molecules attached to their surfaces. Half of all the particles can contain pH buffer salts that control pH to between around pH 3.5 to pH 4.5. A second half of the particles can contain Iodide and iodate salts. When pH particles and iodate/iodide particles are bound next to each other, molecular iodine is released in a controlled fashion. Molecular iodine is effective biocide. In an alternate embodiment, there can be two distinct populations of particles, one with epithelial cell binding molecules and one with lymphocyte-binding molecules. Again, half of all the particles can contain a pH buffer and half iodide and iodate salts. | 2010-12-09 |
20100310622 | DRY EYE TREATMENT BY PUNCTA PLUGS - A punctal plug and method of treating dry eyes are provided. The punctal plug has two or three layer structure and contains at least one drug, for treating conditions such as dry eyes contained in a core, a potion of which is covered by a drug impermeable shell such that drug can radially diffuse from the core. The punctal plug can be inserted into a patient's upper punctum, lower punctum, or both to deliver the drug for an extended period of time. The drug for treating dry eyes can be, for example, cyclosporine A. The plug can also be used for extended delivery of ophthalmic drugs. | 2010-12-09 |
20100310623 | Synergetic functionalized spiral-in-tubular bone scaffolds - An integrated scaffold for bone tissue engineering has a tubular outer shell and a spiral scaffold made of a porous sheet. The spiral scaffold is formed such that the porous sheet defines a series of spiral coils with gaps of controlled width between the coils to provide an open geometry for enhanced cell growth. The spiral scaffold resides within the bore of the shell and is integrated with the shell to fix the geometry of the spiral scaffold. Nanofibers may be deposited on the porous sheet to enhance cell penetration into the spiral scaffold. The spiral scaffold may have alternating layers of polymer and ceramic on the porous sheet that have been built up using a layer-by-layer method. The spiral scaffold may be seeded with cells by growing a cell sheet and placing the cell sheet on the porous sheet before it is rolled. | 2010-12-09 |
20100310624 | CROSSLINKED BIOABSORBABLE MEDICAL DEVICES - The present invention is directed to bioabsorbable medical devices which are introduced into the body of a subject in a first configuration and deformed in the subject's body to a second configuration. The devices generally include at least one bioabsorbable expandable device component that comprises at least one type of biodegradable polymer. In accordance with an aspect of the invention, the expandable device component is crosslinked while in an expanded configuration. The crosslinked device component is then heated to a temperature above the glass transition temperature (Tg) of the material forming the device component. Upon heating to this temperature, the device component is compressed into a contracted configuration and cooled to below the Tg of the material to maintain the contracted configuration. | 2010-12-09 |
20100310625 | METHODS FOR PURIFYING INSOLUBLE BONE GELATIN - The present invention provides methods for purifying insoluble bone gelatin and uses for insoluble bone gelatin. The process for isolating insoluble bone gelatin from bone tissue includes grinding the bone tissue into bone powder; washing the bone powder with saline; demineralizing the bone tissue; contacting the bone powder with a neutral salt; and contacting the bone powder with a stabilizer. The present invention also discloses an insoluble bone gelatin including about 10 percent growth factor. Insoluble bone gelatin is useful, for example, in preparing impaction bone grafts. | 2010-12-09 |
20100310626 | ERYTHROPOIETIN AND FIBRONECTIN COMPOSITIONS FOR BONE REGENERATION - A method of promoting bone regeneration in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of Erythropoietin and Fibronectin, thereby promoting bone regeneration in the subject, (i) wherein the therapeutically effective amount of the Erythropoietin is selected from the group consisting of: about 1-50 mg/Kg for systemic administration; and about 0.1-50 mg/ml for local administration, and (ii) wherein the therapeutically effective amount of the Fibronectin is selected from the group consisting of: about 100-1000 mg/ml for systemic administration; and about 50-500 mg/ml for local administration. | 2010-12-09 |
20100310627 | Xenotransplant for Stroke Therapy - Disclosed are implant compositions and methods for treatment of neurological diseases of the central nervous system of a mammal. | 2010-12-09 |
20100310628 | PRE-SHAPED USER-FORMABLE MICRO-MEMBRANE IMPLANTS - Precut, user-shapeable, resorbable polymer micro-membranes are disclosed. The micro-membranes are constructed of resorbable polymers, which are engineered to attenuate adhesions and to be absorbed into the body relatively slowly over time. The membranes can formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm, while maintaining adequate strength. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be stored in sterile packages, and can be preshaped with relatively high reproducibility during implantation procedures. | 2010-12-09 |
20100310629 | INTRAPERICARDIAL ANTIARRHYTHMIC DELIVERY - Certain embodiments provide a method, of treating or reducing a risk of postoperative cardiac arrhythmia, including: creating an opening in a mammal's body; advancing a releasing member from outside the body, through the opening, and toward the mammal's heart; positioning the releasing member between a visceral layer and a parietal layer of pericardium of the mammal's heart; and at least partially closing the opening in the body, leaving the releasing member in the pericardial space. In certain embodiments, the releasing member releases an antiarrhythmic drug into the mammal's pericardial space and is configured not to impede significantly a systolic or a diastolic function of the heart while the releasing member resides in the pericardial space. | 2010-12-09 |
20100310630 | COATED SURFACE FOR CELL CULTURE - The invention makes available a keratin coating of a support substrate and a method for the production thereof. This keratin coating is suitable particularly for the in vitro or in vivo culturing of epithelial or endothelial cells and, because of its optical transparency, for microscopy. The keratin coating is prepared by applying or coating keratin in the form of nanoparticles from an aqueous keratin solution or keratin suspension. The solution or suspension does not contain any reducing compounds. The keratin solution is prepared preferably from hair, such as human hair. For the preparation of the coating, keratin is brought into solution or into a suspension of nanoparticles by mixing the keratin with an aqueous composition which contains thiourea, urea, and mercaptoethanol. | 2010-12-09 |
20100310631 | FILAMENT BASED ON HYALURONIC ACID IN THE FORM OF FREE ACID AND METHOD FOR OBTAINING IT - The present invention relates to a method for preparing by wet spinning a continuous filament based on hyaluronic acid in free acid form, notably soluble in water. The preparation method according to the invention comprises the following steps: a) preparing a spinnable aqueous solution of hyaluronic acid or of a hyaluronic acid salt, preferably a sodium hyaluronate solution; b) extruding said solution to an extrusion die; c) forming the filament by passing the extruded solution into a bath of acetic acid, concentrated to more than 80%, drawing and drying. The invention also relates to a filament based on hyaluronic acid in free acid form, said filament having swelling properties in water and physiological liquids and moreover being solubilizable in water under certain conditions. | 2010-12-09 |
20100310632 | MICRO-MEMBRANE IMPLANT WITH CUSPED OPENING - Precut, user-shapeable, resorbable polymer micro-membranes having cusped orifices are disclosed. The micro-membranes are constructed of resorbable polymers, which are engineered to attenuate adhesions. The membranes can formed to have very thin thicknesses, for example, thicknesses between about 0.010 mm and about 0.300 mm, while maintaining adequate strength. The membranes can be extruded from polylactide polymers having a relatively high viscosity property, can be stored in sterile packages, and can be preshaped with relatively high reproducibility during implantation procedures. | 2010-12-09 |
20100310633 | CHITINOSANASE - A chitinosanase obtainable from the fungus | 2010-12-09 |
20100310634 | TRANSDERMAL THERAPEUTIC SYSTEM HAVING UREA COMPONENTS - The invention relates to a transdermal therapeutic system (TTS) for administering pharmaceutical agents through the skin, comprising a back layer (R) impermeable to the agent and at least one layer (S) comprising the agent, wherein the layer (H) facing the skin comprises urea in solid form, allowing continuous administration of large quantities of agent over a long period of time. | 2010-12-09 |
20100310635 | Compositions and Methods for Regulating T-Cell Activity - Methods, compositions and kits effective for modulating and immunomonitoring of Treg activity are provided. Therapeutic methods involving formation and uses of cleaved Foxp3 are disclosed, as well as screening assays for identifying agents effective for modulating Treg activity. | 2010-12-09 |
20100310636 | STEARICALLY STABILIZED UNILAMILAR VESICLES, PROCESS FOR PREPARATION THEREOF AND USE THEREOF - The present invention relates to modified formulations of recombinant human glycoprotein having an in-vivo biological activity to increase the production of reticulocytes and red blood cells. A stearically stabilized unilamillar vesicles (SSUV) containing the said biopharmaceutical composition and process for preparation thereof is provided. The pharmaceutical composition comprises a various lipids, covalently modified lipids with polyethylene glycol and or neutral detergent to form long circulating and tightly packed lipid vesicles, which reduced the reticulo-endothelial clearance of SSUV and cause the sustained released effect of encapsulated biopharmaceutical and recombinant human glycoprotein or an erythropoietin moiety. The scope of present invention also describes the process of encapsulation of biopharmaceutical into the SSUV driven by the pH gradient and also the buffer system to enhance the encapsulation efficiency, preventing the protein aggregation and or degradation. | 2010-12-09 |
20100310637 | COMPOSITION AND METHOD FOR THE TREATMENT OR PREVENTION OF GLAUCOMA AND OCULAR HYPERTENSION - This invention relates to compositions and methods for lowering intraocular pressure and treatment and/or prevention of glaucoma and ocular hypertension. The invention provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin peptide and other products of protein/gene engineered modifications of insulin for the lowering of intraocular pressure. The invention also provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein/gene engineered modifications of insulin for increasing the success of glaucoma surgical procedures. The invention further provides insulin, isoforms of insulin, analoges of insulin, fragments of insulin and other products of protein/gene engineered modifications of insulin for neuroprotection of retinal ganglion cells. | 2010-12-09 |
20100310638 | LIPOSOMES COMPRISING DURAMYCIN AND ANTI-VIRAL AGENTS - Disclosed are surprising discoveries concerning the role of anionic phospholipids and aminophospholipids in tumor vasculature and in viral entry and spread, and compositions and methods for utilizing these findings in the treatment of cancer and viral infections. Also disclosed are advantageous antibody, immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases. | 2010-12-09 |
20100310639 | IMMUNO-MODULATORY COMPOSITION - A composition for modulating the immune response in a mammal comprising a pharmaceutically acceptable carrier solution and a plurality of biodegradable nanoparticles, wherein the nanoparticles comprise a targeting moiety that is able to bind selectively to the surface of a T lymphocyte cell and/or of a vascular endothelial cell and wherein the nanoparticles further comprise leukaemia inhibitory factor (LIF). Nanoparticle-mediated targeted delivery of LIF can be used a means to guide tolerogenesis in a patient and has immediate clinical application for recipients of organ grafts and also for patients suffering from autoimmune disease. | 2010-12-09 |
20100310640 | HLA-DR BINDING PEPTIDES AND THEIR USES - The present invention provides HLA-DR (MHC class II) binding peptides derived from the ovarian/breast cancer associated antigens, Human Epidermal Growth Factor Receptor 2 (HER-2/neu), Carcinoembryonic Antigen (CEA), Insulin Growth Factor Binding Protein 2 (IGFBP-2), and Cyclin D1. The immunogenic peptides can be used in cancer vaccines. | 2010-12-09 |
20100310641 | THERAPEUTIC APPROACHES FOR TREATING CMT AND RELATED DISORDERS - The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders. More particularly, the invention relates to combined therapies for treating said disease by affecting PMP22 expression in a subject. | 2010-12-09 |
20100310642 | Topical Drug Delivery Systems for Ophthalmic Use - Topical drug delivery systems for ophthalmic use including mixed nanomicellar formulations of water-insoluble drugs and methods of treating diseases affecting the posterior ocular segments are disclosed. In an embodiment, an aqueous ophthalmic solution includes nanomicelles in a physiologically acceptable buffer, having a pH of 5.0 to 8.0, wherein a corticosteroid at a concentration from about 0.01% w/v to about 1.00% w/v is solubilized through entrapment in a mixed micellar hydrophobic core with a corona composed of hydrophilic chains extending from the hydrophobic core, wherein the nanomicelles comprise vitamin E TPGS at a concentration ranging from about 3.0% w/v to about 5.0% w/v stabilized with octoxynol-40 at a concentration ranging from about 1.0% w/v to about 3.0% w/v. | 2010-12-09 |
20100310643 | CD133 EPITOPES - An immunogen includes an isolated peptide that includes the amino sequence of any one of SEQ ID NOs:1-21 with four or fewer amino acid substitutions. | 2010-12-09 |
20100310644 | ANTI-DANDRUFF COMPOSITIONS CONTAINING PEPTIDES - The present invention relates to the use of special peptides in composition which can be used in particular in hair and skin cosmetics, and to such peptide-containing compositions. In particular, the present invention relates to the use of such peptides as active ingredient for inhibition or treatment of dandruff which does not accumulate in the body or in the environment. Furthermore, the invention relates to the production of such compositions, to the peptides used themselves, to their production and to coding nucleotide sequences for such peptides, to dispensing systems for such peptides and to screening methods for identifying suitable further peptides. | 2010-12-09 |
20100310645 | METHODS FOR INHIBITING TUMOR CELL PROLIFERATION - The subject invention concerns methods for inhibition of STAT biological functions using platinum complexes. | 2010-12-09 |
20100310646 | SELECTIVE EXOSITE INHIBITION OF PAPP-A ACTIVITY AGAINST IGFBP-4 - The present invention relates in one embodiment to PAPP-A exosite(s) interactors such as antibodies which bind to a region comprising LNR3 of PAPP-A and efficiently inhibit proteolysis of IGFBP-4, but not -5. The region comprising LNR3 represents a substrate binding exosite, which can be targeted for selective proteolytic inhibition. Accordingly, the present invention relates in one embodiment to differential inhibition of natural protease substrates by exosite targeting. | 2010-12-09 |
20100310647 | Enzymatic Synthesis of Polymers - The invention relates to new methods of enzymatic synthesis of polymers such as polyorganosilicones and polyesters, and new polymers made by these methods. | 2010-12-09 |
20100310648 | PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL 2 FAMILY INHIBITOR - The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders. | 2010-12-09 |
20100310649 | SOLID LIPID MICROCAPSULES CONTAINING GROWTH HORMONE INNER CORE MICROPARTICLES - The invention relates to growth hormone (GH) formulations having sustained-release properties, in particular human growth hormone (hGH) and methods for their preparation. The growth hormone formulations can be manufactured without denaturing of the protein and can conveniently be administrated to the person in need thereof by using a conventional syringe via a needle having a small diameter. | 2010-12-09 |
20100310650 | Pharmaceutical composition for the oral administration of omega polyenoic fatty acids and one or more active principles incompatible therewith, and a process for its preparation - A pharmaceutical composition for the oral administration of omega polyenoic fatty acids combined with one or more active principles incompatible therewith, is described; also described is a process for preparing said pharmaceutical composition. | 2010-12-09 |
20100310651 | SOLID PHARMACEUTICAL COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION - This invention provides novel solid pharmaceutical compositions and processes for the bulk production of said compositions. This invention also provides methods of using the pharmaceutical compositions in the treatment of cancer. | 2010-12-09 |
20100310652 | COATED EXTENDED RELEASE PHARMACEUTICAL COMPOSITIONS OF LEVETIRACETAM - An extended release pharmaceutical composition comprising levetiracetam. A coated extended release pharmaceutical composition comprising levetiracetam wherein the core is coated with a rate controlling composition. | 2010-12-09 |
20100310653 | USE OF AN EXTRACT MADE OF LEAVES OF GINKGO BILOBA - The present invention relates to the use of an extract made of leaves of | 2010-12-09 |
20100310654 | HOMEOPATHIC REMEDIES FOR USE BEFORE AND AFTER AESTHETIC INJECTABLE AND SURGICAL PROCEDURES TO MINIMIZE SWELLING AND BRUISING - The present invention generally relates to all-in-one homeopathic remedies for use before and after aesthetic injectable treatment and/or surgical procedures to help minimize swelling and bruising. | 2010-12-09 |
20100310655 | Crystal modification A of 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide and dosage forms and formulations thereof - The invention relates to dosage forms and formulations comprising the novel crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide, wherein crystal modification A is characterized by characteristic lines with interplanar spacings (d values) of 10.5 Å, 5.14 Å, 4.84 Å, 4.55 Å, 4.34 Å, 4.07 Å, 3.51 Å, 3.48 Å, 3.25 Å, 3.19 Å, 3.15 Å, 3.07 Å, and 2.81 Å, determined by means of an X-ray powder pattern. Dosage forms of crystal modification A of the compound I-(2, 6-difluorobenzyl)-I H-I,2,3-triazole-4-carboxamide may be for oral or parenteral administration, in the form of a solid or liquid, and in a dosage range of 20 mg to less than 500 mg. Solid dosage forms comprise a tablet or capsule, and further comprise a pharmaceutically-acceptable carrier and film-coat. | 2010-12-09 |
20100310656 | Immunotherapy and prevention of autoimmune hepatitis - The invention is within the field of immunology and microbiology, more specifically the field of virology and is related to immunotherapy and prophylaxis of hepatitis and autoimmune diseases. The composition useful for these purposes is disclosed, including the methods of making and using said composition. | 2010-12-09 |
20100310657 | PHARMACEUTICAL COMPOSITION FOR TREATMENT AND PREVENTION OF KIDNEY DISEASES - Provided is a pharmaceutical composition for the treatment and prevention of kidney diseases, containing (a) a therapeutically effective amount of a compound represented by Formulae 1 or 2 or a pharmaceutically acceptable salt, prodrug, solvate or isomer thereof, and (b) a pharmaceutically acceptable carrier, diluent or excipient or any combination thereof. | 2010-12-09 |
20100310658 | Electroprocessed Fibrin-Based Matrices and Tissues - The invention is directed to formation and use of electroprocessed fibrin as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed fibrin may also be combined with other molecules in order to deliver the molecules to the site of application or implantation of the electroprocessed fibrin. The fibrin or fibrin/cell suspension is electrodeposited onto a substrite to form the tissues and organs. | 2010-12-09 |
20100310659 | Compositions and Uses Thereof - Provided are solid dispersions, solid molecular complexes, salts and crystalline polymorphs involving propane- | 2010-12-09 |
20100310660 | DRY POWDER MICROPARTICLES FOR PULMONARY DELIVERY - The invention provides a dry powder microparticle for pulmonary delivery, which comprises at least one nanoparticle in the form of liposome or micelle wherein the nanopaparticle encapsulates one or more therapeutic agent therein, and a diluent layer surrounding the nanaparticles. | 2010-12-09 |
20100310661 | ORAL FORMULATIONS FOR PICOPLATIN - The invention provides formulations for the organoplatinum anticancer drug picoplatin. Self emulsifying compositions, stabilized nanoparticulate compositions, solid dispersions, and nanoparticulate suspensions in oils are provided, along with methods for preparation of the formulations. The formulations can provide improved oral availability of picoplatin relative a to a simple solution of picoplatin such as in water or normal saline solution and can be used in combination therapy. | 2010-12-09 |
20100310662 | Oral Drug Delivery System for Azole, Moxifloxacin and Rifampicin - An oral drug delivery system for treatment of tuberculosis is described. The oral drug delivery system includes (e.g., a mixture or combination of): poly DL-lactide-co-glycolide nano particles having encapsulated an azole therein; poly DL-lactide-co-glycolide nano particles having moxifloxacin encapsulated therein; and poly DL-lactide-co-glycolide nano particles having RIF encapsulated therein | 2010-12-09 |
20100310663 | PHARMACEUTICAL COMPOSITIONS COMPRISING NANOPARTICLES AND A RESUSPENDING MATERIAL - A pharmaceutical composition comprises nanoparticles comprising a poorly water-soluble drug and a poorly aqueous soluble polymer, and a resuspending material selected from the group consisting of hydroxypropyl methyl cellulose acetate succinate, carboxymethyl ethylcellulose, and pharmaceutically acceptable salt forms thereof. | 2010-12-09 |
20100310664 | COMPOSITIONS AND METHODS FOR TREATING INSULIN RESISTANCE AND DIABETES MELLITUS - Provided are electrokinetically-altered fluids (gas-enriched electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide modulation of at least one of cellular membrane potential and cellular membrane conductivity, and therapeutic compositions and methods for use in treating diabetes and diabetes-associated conditions or disorders (e.g., insulin resistance), or symptoms thereof. Provided are electrokinetically-altered ioinic aqueous fluids optionally in combination with other therapeutic agents. Particular aspects provide for regulating or modulating intracellular signal transduction associated with said inflammatory responses by modulation of at least one of cellular membranes, membrane potential, membrane proteins such as membrane receptors, including but not limited to G-Protein Coupled Receptors (GPCR), and intercellular junctions (e.g., tight junctions, gap junctions, zona adherins and desmasomes). Other embodiments include particular routes of administration or formulations for the electrokinetically-altered fluids (e.g., electrokinetically-altered gas-enriched fluids and solutions) and therapeutic compositions. | 2010-12-09 |
20100310665 | BACTERIOSTATIC OR BACTERIOCIDAL COMPOSITIONS AND METHODS - Particular aspects provide compositions and methods for treating bacterial infection or at least one symptom related to bacterial infection in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically-altered fluid (including gas-enriched electrokinetically altered fluids) which comprise an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures in an amount sufficient to provide, upon contact with a cell, modulation of at least one of cellular membrane potential and cellular membrane conductivity. The electrokinetically-altered ionic fluid compositions are sufficient to provide for modulation of intracellular signal transduction, wherein treating bacterial infection or at least one symptom related to bacterial infection is thereby afforded. In particular embodiments, the fluids are gas-enriched fluids or therapeutic compositions and methods, and include oxygen-enriched ionic aqueous solutions optionally in combination with other therapeutic agents. Other embodiments include particular routes of administration or formulations for the gas-enriched therapeutic compositions. | 2010-12-09 |
20100310666 | Delivery of Functional Compounds - Functional ingredients including an esterified component and microencapsulated in an enteric matrix to increase the microencapsulation efficiency and reduce undesired organoleptic properties of the microencapsulated material while providing a desired release rate and ester hydrolysis rate, the process including forming an emulsion in water and titrating the emulsion with a precipitating agent to produce a particulate precipitate. | 2010-12-09 |
20100310667 | CONTROLLED-RELEASE FLOATING PHARMACEUTICAL COMPOSITIONS - The invention relates to a pharmaceutical composition comprising a plurality of controlled-release coated microparticles each comprising a floating core, on the surface of which is deposited a layer containing at least one active principle, said layer being covered with a controlled-release coating, characterized by the fact that said floating core is composed of cellulose acetate phthalate and has an apparent density of less than or equal to 0.6 g/mL and said coated microparticles have a density of less than or equal to 0.7 g/mL. | 2010-12-09 |
20100310668 | PHARMACEUTICAL COMPOSITIONS COMPRISING N-[2-(DIETHYLAMINO)ETHYL]-5-[(5-FLUORO-1,2-DIHYDRO-2-OXO-3H-INDOL-3-YLIDE- NE)METHYL]-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXAMIDE - The present invention relates to a pharmaceutical composition comprising N-[2-(diethylamino)ethyl]-5-[(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient. | 2010-12-09 |
20100310669 | Dispersion of Poloxamer- Protein Particles, Methods of Manufacturing and Uses Thereof - The present invention relates to a method for preparing poloxamer-protein particles. It also relates to poloxamer-protein particles obtainable by this method, dispersion thereof, and their use in methods of encapsulation, in particular of microencapsulation. | 2010-12-09 |
20100310670 | SUSTAINED-RELEASE MICROSPHERE CONTAINING SHORT CHAIN DEOXYRIBONUCLEIC ACID OR SHORT CHAIN RIBONUCLEIC ACID AND METHOD OF PRODUCING THE SAME - A sustained-release microsphere formulation containing a short chain deoxyribonucleic acid or a short chain ribonucleic acid as an active ingredient, which has improved sustained-release properties and long-lasting efficacy, is provided. A fine particle formulation, encapsulating stably a short chain deoxyribonucleic acid or a short chain ribonucleic acid, being capable of inhibiting, for a long period, expression of a specific protein related to a disease, and which can be administered by injection or transmucosally, and a production method of the same are provided. A sustained-release microsphere formulation containing a short chain deoxyribonucleic acid or a short chain ribonucleic acid, particularly siRNA, as an active ingredient, especially a sustained-release microsphere prepared through a w | 2010-12-09 |
20100310671 | ENCAPSULATED LOW VISCOSITY HYDROPHOBIC LIQUID ACTIVES - The present invention provides personal care compositions, as well as methods for protecting low viscosity hydrophobic liquid actives. | 2010-12-09 |
20100310672 | DISINFECTANT BASED ON AQUEOUS; HYPOCHLOROUS ACID (HOCI)-CONTAINING SOLUTIONS; METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF - Disclosed are a disinfectant based on an aqueous, hypochlorous acid-containing solution, especially in the form of an electrochemically activated, diluted water/electrolyte solution, as well as a method for producing such a disinfectant. In order to increase the stability of such a disinfectant also in case the disinfectant has a large surface, e.g. when the disinfectant is applied to surfaces, the disinfectant further contains a certain percentage of amorphous silica (SiO | 2010-12-09 |
20100310673 | SUBSTANCE AND COMPOSITION BOTH CAPABLE OF IMPARTING HEAT RESISTANCE - An agent for thermally stabilizing lactoferrin, which comprises a nucleic acid as an active ingredient, can be added to lactoferrin to impart thermal stability to lactoferrin. Thermally stabilized lactoferrin can be heat-sterilized at a pH value around a neutral pH value while keeping its activity. | 2010-12-09 |
20100310674 | NOVEL COMPOSITION FOR TREATING THE SIDE EFFECTS OF ANTICANCER TREATMENTS - The invention relates to novel compositions, particularly pharmaceutical, comprising, as active ingredients, at least one cytotoxic agent and at least one cholest-4-en-3-one oxime derivative. | 2010-12-09 |
20100310675 | AMINOPYRIMIDINES USEFUL AS KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising those compounds and methods of using the compounds and compositions in the treatment of various disease, conditions, and disorders. The invention also provides processes for preparing compounds of the invention. | 2010-12-09 |
20100310676 | BIOCIDES AND APPARATUS - A biocide is formed by mixing at least one of ammonium sulfamate and ammonium carbamate with an aqueous solution of a hypochlorite oxidant at a molar ratio of ammonium to hypochlorite of at least 1:1. The biocide is useful in treating microbial or biofilm growth, pulp and paper process water, cooling tower water, waste water, reclaimed waste water, sludge, colloidal suspensions, irrigation water or a medium having a reducing capacity. | 2010-12-09 |
20100310677 | STABLE AMORPHOUS CALCIUM CARBONATE COMPRISING PHOSPHORYLATED AMINO ACIDS - Provided are compositions containing amorphous calcium carbonate (ACC), and at least one phosphorylated amino acid which stabilizes the amorphous form of said calcium carbonate. The compositions are useful in pharmaceutical and nutraceutical formulations. | 2010-12-09 |
20100310678 | Compositions and Methods for Nutrition Supplementation - The present invention relates to compositions, that may be swallowable, chewable or dissolvable, comprising various vitamins and minerals, and in a specific embodiment, comprise vitamin B | 2010-12-09 |
20100310679 | NOVEL COMPOSITIONS FOR CONTROL OF MALICIOUS MARINE ANEMONES - The present invention relates to improved compositions for controlling marine pest anemones, to methods of application of same, and to kits for the convenient dispensing of such compositions. | 2010-12-09 |
20100310680 | COMPOSITION AND METHOD FOR TREATING ACNE - This invention relates to a novel composition and method useful for the treatment of acne, and more particularly, to a composition and method for reducing an appearance of post acne marks and scars without skin irritation in a short amount of time. | 2010-12-09 |
20100310681 | Modulation of KCNQ Potassium Channel Activity for Treatment of Psychiatric Disorders and the Symptoms Thereof - Disclosed herein are compositions and methods for treating a psychiatric disorder or symptoms thereof in a patient. The compositions comprise a compound that modulates KCNQ (Kv7) potassium channel activity and the methods include administering an effective amount of the compound that modulates KCNQ (Kv7) potassium channel activity. | 2010-12-09 |
20100310682 | PHARMACEUTICAL COMPOSITIONS FOR TREATING ANXIETY - Pharmaceutical compositions or functional foods for treating anxiety comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating diazepam in the art, the present invention has significant anxielytic efficacy. | 2010-12-09 |
20100310683 | PHARMACEUTICAL COMPOSITIONS FOR TREATING DEPRESSION AND ANXIETY - Pharmaceutical compositions or functional foods for treating depression and anxiety comprising ginseng saponin (Rg1+Rb1), glycyrrhizic acid and jujuba cAMP. Experiments demonstrate that as compared with the preferred drug for treating depression and anxiety paroxetine and diazepam in the art, the present invention has significant anti-depression and anxielytic efficacy. | 2010-12-09 |
20100310684 | METHODS FOR TREATING AND PREVENTING MUCOSITIS - Methods for treating and preventing mucositis, in particular mucositis following the administration of chemotherapy drugs or a combination of said drugs with radiotherapy, are disclosed herein. More specifically, disclosed herein is the administration of a therapeutically effective amount of at least one of an anthocyanoside, a proanthocyanidin, or an extract containing at least one of an anthocyanoside or a proanthocyanidin for the treatment or prevention of mucositis. The therapeutically effective amount of the anthocyanoside, proanthocyanidin or extract can be administered alone or in combination with a therapeutically effective amount of at least one of an anti-inflammatory agent, immunomodulating agent, analgesic, antimicrobial agent or antifungal agent. Also disclosed herein are pharmaceutical compositions for treating and preventing mucositis. | 2010-12-09 |
20100310685 | PUPICIDAL AND LARVICIDAL COMPOSITION - A pupicidal and larvicidal composition which comprises, predominantly and in proportions which can vary from approximately 0% to approximately 100%, cetyl alcohol, and wherein the rest of the composition, where necessary, is also constituted by at least one excipient. | 2010-12-09 |
20100310686 | EXTRACTS OF DESCHAMPSIA ANTARCTICA DESV, WITH ANTINEOPLASTIC ACTIVITY - The present disclosure provides a novel antineoplastic extract obtained from | 2010-12-09 |
20100310687 | ANTI-GASTRITIS AND ANTI-ULCER AGENT CONTAINING MOMORDICAE SEMEN EXTRACT AND MOMORDICA SAPONIN I ISOLATED FROM THE SAME - The present invention relates to a Momordicae semen extract effective in the prevention and treatment of gastritis or gastric ulcer and | 2010-12-09 |
20100310688 | ACACIA EXTRACTS AND THEIR COMPOUNDS ON INHIBITION OF XANTHINE OXIDASE - The present invention relates to a composition for inhibiting xanthine oxidase comprising an effective amount of the extracts from | 2010-12-09 |
20100310689 | Method for Producing Hippocastanaceae Plant Seed Extract - To provide a method for producing a Hippocastanaceae plant seed extract which is less colored and is suitably incorporated into a composition such as a pharmaceutical product or a cosmetic composition. A method for producing a Hippocastanaceae plant seed extract, which includes removing hulls from seeds of a Hippocastanaceae plant, followed by extraction with a solvent. | 2010-12-09 |
20100310690 | Pharmaceutical product and analysis model for hormone replacement therapy for women and prevention of some cancers and uterine myomas - The present disclosure describes a study of estrogenic activity present in various plant species, selectively inducing some but not all estrogenic responses in the uterus. Prepubertal female rats were treated sequentially with various extracts or decoctions of different plant species or its vehicle, followed 1 h later by treatment with estradiol-17β (E) or its solvent. Uteri were excised under anesthesia and histologically processed for eosinophil quantification and morphometric evaluation of various uterine responses to estrogen, at 6 or 24 h after hormone or vehicle treatment. Besides extracts or decoctions, pure phytoestrogens were also used. Additionally, human mammary cancer cells MCF-7 or MDAMB-231 were cultured in presence of the extract (or decoction), E, both or solvent and cell proliferation was evaluated. Various extracts or decoction displayed selective estrogenic and/or antiestrogenic action for some but not all parameters of estrogen stimulation in the uterus and inhibited growth of human mammary cells in culture or antagonized the estrogen-induced increase in their growth. Present results reveal, for the first time, a dissociation of responses to estrogen by phytoestrogens, suggesting its possible therapeutic application as estrogenic compounds not inducing cell proliferation and reveal the anticancerous effect of some of the extracts with possible therapeutic relevance. The dissociation of responses to estrogen additionally suggest therapeutic applications in estrogen-related diseases (for instance, premenstrual syndrome, endometriosis, etc.); the inhibition of eosinophil degranulation suggest an application in diseases related to eosinophils (hypereosinophilic syndrome, allergic and hypersensitivity diseases). | 2010-12-09 |
20100310691 | Blow Molding Machine for Producing Hollow Bodies from Heated Preforms - A blow molding machine for producing hollow bodies from heated preforms has at least one blow mold and at least one blow nozzle which can be moved vertically relative with respect to each other via a drive. To design the drive more flexibly, an electromagnetic drive is employed. | 2010-12-09 |
20100310692 | PLODDER MACHINE - A plodder machine includes a raw material receiving member, a forming member mounted to a bottom of the receiving member to define a receiving space therebetween, a rolling device mounted in the receiving space, and a mounting base supporting the forming member and a power transmission device thereon. The rolling device is driven by the power transmission device to rotate horizontally and thereby press a raw material into a plurality of forming holes circularly arrayed on the forming member to form bar-shaped products. A screening discharging device is connected to the mounting base and located below the forming member to catch and separate the bar-shaped products from recyclable raw material fragments at reduced labor and time costs. Forming sleeves each having a bore of different cross sectional shape and size can be selectively fitted in the forming holes to change the cross-sectional shapes and sizes of the bar-shaped products. | 2010-12-09 |
20100310693 | EXTRUDER SCREW FOR A SCREW EXTRUDER - The invention concerns an extruder screw ( | 2010-12-09 |
20100310694 | APPARATUS FOR CONTROLLING MELT FLOW IN A MELT DISTRIBUTION NETWORK - According to embodiments of the present invention, there is provided an apparatus for controlling melt flow through a portion of the melt distribution network. A flow control device is provided. The flow control device comprises a body defining: a mixer configured to be positioned in a conduit for providing a path of flow for melt such that the mixer traverses substantially the whole cross-section of the path of flow; a temperature control portion associated with the mixer for actively controlling temperature of the mixer. | 2010-12-09 |
20100310695 | FLOATING CUT-OFF BAR AND METHOD OF USE THEREOF - A floating cut-off bar that follows a preselected path of travel over a mold box during a block production cycle. The floating cut-off bar may be coupled to a feed drawer whereby a mechanism allows the floating cut-off bar to engage the specified contour of a division plate in a mold box assembly and aid in material distribution by screeding excess material and delivering additional material to areas of the mold box as necessary and method of making wall blocks therefrom. The specified contour of the division plate is designed to optimally deliver material to achieve a specified uniform density of the block produced for greater structural integrity, strength and durability of the block. | 2010-12-09 |
20100310696 | Pre-loading mechanism for a tilting platen in a thermoforming press - A tilting platen pre-loading system for thermoforming press the system pre-loads a tilting thermoforming press platen with a specialized spring-loaded hammer and anvil assembly, to provide better efficiency and consistency in the high speed, cyclic operation of the thermoforming press. The anvil assembly includes an anvil base and an anvil, and the anvil base is immovably mounted to a tilt-frame. The anvil is maintained separate from the anvil base by a loading spring, which are preferably conical or Belleville washers. The tilting platen is rotatably mounted within the tilt-frame and a platen hammer immovably mounts to the tilt-frame. The loading spring compresses and retracts the anvil as the hammer contacts the anvil, and the tilting platen rotates on the tilt-frame to align the tilting platen with a receiving platen. The loading spring de-compresses and extends the anvil as the hammer separates from the anvil, and the tilting platen rotates on the tilt-frame away from the over-platen. | 2010-12-09 |
20100310697 | INJECTION MOLDING MACHINE - An injection molding machine ( | 2010-12-09 |
20100310698 | DEVICE AND METHOD FOR THE GENERATIVE PRODUCTION OF THREE-DIMENSIONAL OBJECTS ON THE BASIS OF A MULTIPHASE SYSTEM - The invention relates to a device and to a method for the production of a three-dimensional object by the consecutive layered bonding of a material that can be bonded by means of electromagnetic radiation, wherein in the so-called vat an at least n-phase system, where n>2, is present, of which at least one phase comprises the building material and at least one other a phase that cannot be mixed with the building material. | 2010-12-09 |